Antifibrillatory Effect of Esmolol Alone and in Combination with Lidocaine
- 1 March 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 27 (3), 376-382
- https://doi.org/10.1097/00005344-199603000-00010
Abstract
The primary objective of this study was to determine the effect of esmolol, administered alone and in combination with lidocaine, on ventricular fibrillation threshold (VFT) in pigs. A secondary objective was to determine the relationship between blood esmolol concentrations and VFT. We determined VFT using a train of electrical stimuli delivered to the right ventricle after eight paced beats at a basic cycle length of 285 ms. Current was increased in 2-mA increments until VF occurred. VFT determinations were performed during administration of esmolol 1,000 mu g/kg/min, during a continuous infusion of lidocaine, and during infusion of esmolol and lidocaine in combination. Mean increases in VFT from baseline during infusion of esmolol and lidocaine alone were 32.3 +/- 12.9 and 8.5 +/- 7.2 mA, respectively (p < 0.05, each drug compared with baseline; p < 0.05, esmolol vs. lidocaine). Mean increase in VFT from baseline during infusion of the combination was 52.0 +/- 22.0 mA (p < 0.05 as compared with baseline and with esmolol or lidocaine alone). The relationship between blood esmolol concentrations and VFT was described by a counterclockwise hysteresis curve, suggesting delay in equilibration of esmolol between blood and site of effect. The antifibrillatory efficacy of esmolol is significantly greater than that of lidocaine in this model. Administration of the two agents in combination resulted in significantly greater antifibrillatory efficacy than that associated with either drug administered alone.Keywords
This publication has 31 references indexed in Scilit:
- Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part III. Adult advanced cardiac life supportJAMA, 1992
- Antifibrillatory effects of lidocaine and bretylium immediately postcardiopulmonary resuscitationAmerican Heart Journal, 1985
- A Classification of Antiarrhythmic Actions Reassessed After a Decade of New DrugsThe Journal of Clinical Pharmacology, 1984
- Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metaboliteClinical Pharmacology & Therapeutics, 1983
- Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administrationBiopharmaceutics & Drug Disposition, 1982
- Experience with bretylium tosylate by a hospital cardiac arrest team.Circulation, 1977
- Lidocaine in the Prevention of Primary Ventricular FibrillationNew England Journal of Medicine, 1974
- The Comparative Antiarrhythmic Actions of Lidocaine and its Quarternary Derivative, Methyl LidocaineCirculation, 1974
- Effect of Lidocaine on the Ventricular Fibrillation Threshold in the Dog during Acute Ischemia and Premature Ventricular ContractionsCirculation, 1972
- Effectiveness of Bretylium Tosylate against Refractory Ventricular ArrhythmiasCirculation, 1972